Literature DB >> 8948270

The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.

A R Cabral1, M C Amigo, J Cabiedes, D Alarcon-Segovia.   

Abstract

BACKGROUND: Most systemic lupus erythematosus (SLE) patients with two or more clinical manifestations of the antiphospholipid syndrome (APS) and negative antiphospholipid antibodies (aPL) have antibodies to beta 2-glycoprotein-I (a beta 2 GP-I). Herein we describe a similar set of circumstances, but in patients without evidence of SLE. PATIENTS AND METHODS: We studied 6 patients with recurrent venous and/or arterial thromboses without aPL as detected by routine assays nor clinical or serological evidence of other autoimmune disease. Immunoglobin (Ig) G and IgM antibodies to bovine and human phospholipid-free beta 2 GP-I were studied by Western blot test and by enzyme-linked immunosorbent assay (ELISA) utilizing radiated and nonirradiated plates. We also tested antibodies to cardiolipin, phosphatidylserine, and phosphatidylethanolamine by ELISA. As controls, 54 normal sera were studied.
RESULTS: All 6 patients had recurrent arterial and/or venous thromboses. Three also had thrombocytopenia, 1 had livedo reticularis, and 2 had valvular heart disease. None of the patients had aPL, but all had serum IgG reactivity against human and bovine beta 2 GP-I (P < 0.001 versus controls for both). Titers of anti-bovine beta 2 GP-I were higher when studied in irradiated plates but were also higher than normal in nonirradiated plates (P < 0.001). These antibodies did not recognize human or bovine beta 2 GP-I bound to cardiolipin in solid phase. We confirmed by Western blot that these autoantibodies recognize human beta 2 GP-I. We found no IgM a beta 2 GP-I.
CONCLUSIONS: We describe a primary condition akin to the antiphospholipid syndrome with negative aPL, but with serum IgG antibodies to human and bovine beta 2 GP-I. These antibodies recognize beta 2 GP-I epitopes that are not accessible when beta 2 GP-I is bound to cardiolipin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948270     DOI: 10.1016/s0002-9343(96)00254-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Antiphospholipid antibody tests: spreading the net.

Authors:  M L Bertolaccini; S Gomez; J F P Pareja; A Theodoridou; G Sanna; G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

2.  Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage.

Authors:  B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; G Palladini; G Valesini
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio.

Authors:  Colum F Amory; Steven R Levine; Robin L Brey; Mulugeta Gebregziabher; Stanley Tuhrim; Barbara C Tilley; Ann-Catherin C Simpson; Ralph L Sacco; Jay P Mohr
Journal:  Cerebrovasc Dis       Date:  2015-10-29       Impact factor: 2.762

4.  Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients.

Authors:  Kamil Bugała; Adam Mazurek; Krzysztof Gryga; Monika Komar; Grzegorz Kopeć; Jacek Musiał; Piotr Podolec; Carlo Perricone; Wojciech Płazak
Journal:  Clin Rheumatol       Date:  2018-04-20       Impact factor: 2.980

5.  Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome.

Authors:  Virunya Parkpian; Oravan Verasertniyom; Monchand Vanichapuntu; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Prapaporn Pisitkul; Pantep Angchaisuksiri; Napaporn Archararit; Bupha Rachakom; Katcharin Ayurachai; Suchela Janwityanujit
Journal:  Clin Rheumatol       Date:  2007-03-02       Impact factor: 2.980

6.  Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation.

Authors:  Sherry D Fleming; Michael R Pope; Sara M Hoffman; Tiffany Moses; Urska Bukovnik; John M Tomich; Lynn M Wagner; Keith M Woods
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

Review 7.  Annexin A2: biology and relevance to the antiphospholipid syndrome.

Authors:  E Cockrell; R G Espinola; K R McCrae
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 8.  Obstetric antiphospholipid syndrome.

Authors:  Aleksandra Antovic; Maria Sennström; Katarina Bremme; Elisabet Svenungsson
Journal:  Lupus Sci Med       Date:  2018-09-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.